Cholecystokinin octapeptide improves cardiac function by activating cholecystokinin octapeptide receptor in endotoxic shock rats

Figure 1 Changes of mean heart rate (HR) after intravenous injection of sCCK-8 or proglumide to ES rats. (mean±SD, n = 6). ^bP<0.01 vs control; ^dP<0.01 vs LPS group.

Figure 2 Changes in MAP and LVP after intravenous injection of sCCK-8 or proglumide to ES rats. (mean±SD, n = 6). ^bP<0.01 vs control; ^dP<0.01 vs LPS group.

Figure 3 Changes in ±LVdp/dt_max after intravenous injection of sCCK-8 or proglumide to ES rats. (mean±SD, n = 6) ^bP<0.01 vs control, ^dP<0.01 vs LPS.

Figure 4 Expression of CCK-A/BR and β-actin mRNA of RT-PCR in the myocardium of ES rats. (mean±SD, n = 3) ^aP<0.05 vs control, ^bP<0.01 vs control. A: Representative pictures of CCK-AR (630 bp); B: representative pictures of CCK-BR (320 bp); C: representative pictures of β-actin (420 bp). Lane 1: DNA marker, lane 2: products expressed from kidney tissue as a positive control, lane 3: products expressed from control-saline-treated, lanes 4-7: products expressed from LPS-treated at 0.5, 2, 6, and 12 h, respectively.